Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension
- 19 March 2015
- journal article
- Published by Springer Nature in Hypertension Research
- Vol. 38 (8) , 539-544
Abstract
The in-hospital mortality of severe pulmonary hypertension (PH) with right heart failure (RHF) is high despite the use of vasoactive and PH-specific therapies. We conducted a prospective analysis evaluating the safety and outcomes of fasudil hydrochloride (Chuan Wei) therapy in acute RHF. PH patients hospitalized between April 2009 and November 2010 were treated with 30 mg of i.v. fasudil three times daily over 30 min, until they experienced relief of RHF symptoms. Adverse and serious adverse events were recorded. Odds ratios (ORs) and 95% confidence intervals were calculated for both in-hospital mortality and re-hospitalization. Multivariate adjustments were made for age, gender and World Health Organization functional class. There were no significant differences between the fasudil group and the control group in demographics, hemodynamics, and PH-specific and vasoactive therapies. Of the 209 study patients, 3 of the 74 patients (4.1%) in the fasudil arm died, and 19 of the 135 patients (14.1%) in the control arm died (P=0.005). Fasudil decreased both in-hospital mortality (OR=0.258 (0.074-0.903); P=0.034) and 30-day re-hospitalization (OR=0.200 (0.059-0.681); P=0.010). Fasudil was well tolerated; one patient discontinued treatment. Intravenous fasudil may be given safely in patients with PH and acute RHF, and may reduce the rates of both in-hospital mortality and 30-day re-hospitalization.Keywords
This publication has 40 references indexed in Scilit:
- Characteristics and Outcome After Hospitalization for Acute Right Heart Failure in Patients With Pulmonary Arterial HypertensionCirculation: Heart Failure, 2011
- Riociguat for the treatment of pulmonary hypertensionExpert Opinion on Investigational Drugs, 2011
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial HypertensionJACC, 2009
- Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problemCurrent Opinion in Pharmacology, 2009
- Acute Vasodilator Effect of Fasudil, a Rho-kinase Inhibitor, in Monocrotaline-Induced Pulmonary Hypertension in RatsJournal of Cardiovascular Pharmacology, 2007
- Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in ratsPharmacological Research, 2007
- Rho Kinase Inhibition Improves Endothelial Function in Human Subjects With Coronary Artery DiseaseCirculation Research, 2006
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Miscellaneous ItemCardiovascular Research, 1997